This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer's (PFE) Late-Stage Meningococcal Jab Study Meets Goal
by Zacks Equity Research
Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.
Pharma Stock Roundup: J&J New Buyback Plan, CHMP Nod to PFE's BA.4, BA.5 Omicron Jab
by Kinjel Shah
J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
3 Mega-Cap Stocks With Unbelievably Strong Free Cash Flow
by Derek Lewis
All three companies generate substantial cash. In fact, one reported the highest quarterly free cash flow of any S&P 500 company in Q2.
Pfizer (PFE) Starts Late-Stage Study on Influenza Vaccine
by Zacks Equity Research
Pfizer (PFE) doses the first participants in the phase III study of its investigational mRNA-based influenza vaccine. The study will enroll nearly 25,000 participants.
Zacks Market Edge Highlights: 3M, Northwest Bancshares, Pfizer, Xerox, Enterprise Products Partners
by Zacks Equity Research
3M, Northwest Bancshares, Pfizer, Xerox, Enterprise Products Partners have been highlighted in this Market Edge article.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $46.15, moving -0.09% from the previous trading session.
How to Have Fun Investing
by Tracey Ryniec
Get paid for being an owner of a business. Collect those dividend checks and watch them compound.
Pfizer (PFE), BioNTech Omicron BA.4, BA.5 Boosters Get CHMP Nod
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) get a positive recommendation from CHMP for Omicron BA.4 and BA.5-adapted bivalent vaccines.
Novavax (NVAX) Gets EU Nod for COVID-19 Booster Jab in Adults
by Zacks Equity Research
Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.
Ideaya (IDYA) Up on Interim Data from Mid-Stage Eye Cancer Study
by Zacks Equity Research
Ideaya Biosciences (IDYA) reports positive interim results from its mid-stage study, evaluating darovasertib in combination with Pfizer's Xalkori (crizotinib) in metastatic uveal melanoma. Stock up.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Pfizer (PFE) Alopecia Drug Filings Get Accepted by FDA, EMA
by Zacks Equity Research
FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.
Pharma Stock Roundup: FDA Nod to AZN's Imfinzi for New Cancer & Other Updates
by Kinjel Shah
FDA approves AstraZeneca's (AZN) Imfinzi combination for advanced metastatic biliary tract cancer and grants Breakthrough Therapy Designation to Pfizer's (PFE) Group B Streptococcus (GBS) vaccine.
Pfizer (PFE) Streptococcus Jab Gets FDA's Breakthrough Tag
by Zacks Equity Research
Pfizer (PFE) gets Breakthrough Therapy Designation for GBS vaccine candidate, GBS6, based on an interim analysis of a phase II study.
Zacks Market Edge Highlights: General Electric, IBM, Pfizer, Bank of America and McDonald's
by Zacks Equity Research
Zacks Market Edge Highlights: General Electric, IBM, Pfizer, Bank of America and McDonald's
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $46.13, moving +0.81% from the previous trading session.
Should Stock Investors Buy and Hold Forever?
by Tracey Ryniec
The pros and cons of buying a bunch of blue-chip stocks and holding them for 20+ years.
Spero (SPRO) Up Following Positive FDA Update for UTI Drug
by Zacks Equity Research
Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Novavax's (NVAX) COVID-19 Jab Gets Approval in Switzerland
by Zacks Equity Research
Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax's (NVAX) COVID-19 Booster Gets CHMP Recommendation
by Zacks Equity Research
The European Medicines Agency's CHMP recommends expanded conditional marketing authorization for Novavax's (NVAX) COVID-19 vaccine as a booster for adults.
Novo Nordisk (NVO) to Tap Into SCD Space With Forma Acquisition
by Zacks Equity Research
Novo Nordisk (NVO) inks agreement to acquire Forma Therapeutics for $1.1 billion. The company is looking to venture into the sickle cell disease and rare blood disorders space.